ASND in the 13F filings
Ascendis Pharma A · CUSIPs 04351P101, K08588103
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 22 Jan 2026
- Managers listing it
- 29
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 14 listed it in both
- Shares listed
- 19,883,899
- combined, among listed positions
- Reported value
- $4.2bn
- combined, at the quarter end
Among the 92 comparable managers: 16 buyers (opened or added shares) and 14 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -441,908.
Managers listing ASND in Q4 2025
29 of 29 holders
Largest increases and reductions, by shares
Increases
- Citadel Advisors LLCexisting position · 519,516 shares now+491,876
- Susquehanna International Group LLPnew position · 470,951 shares now+470,951
- D. E. Shaw & Co.existing position · 125,768 shares now+122,182
- Millennium Management LLCexisting position · 262,329 shares now+87,726
- Two Sigma Investments LPexisting position · 247,892 shares now+64,006
Reductions
- Artisan Partners LPexisting position · 3,225,885 shares now-494,995
- Invesco Ltdexisting position · 586,094 shares now-331,809
- Fidelity (FMR LLC)existing position · 4,153,311 shares now-318,422
- Janus Henderson Group Ltdexisting position · 4,061,641 shares now-261,418
- T. Rowe Price Associates Incexisting position · 1,570,260 shares now-155,968
New positions and exits
New (6)
Exited (3)
- Hudson Bay Capital Management LPwas $16m
- Arrowstreet Capital LPwas $12m
- Neuberger Berman Group LLCwas $4.2m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2017 | 1 | $2.1m | n.a. | n.a. |
| Q3 2017 | 2 | $4.7m | n.a. | n.a. |
| Q4 2017 | 1 | $4.8m | n.a. | n.a. |
| Q1 2018 | 6 | $362m | n.a. | n.a. |
| Q2 2018 | 4 | $310m | n.a. | n.a. |
| Q3 2018 | 3 | $359m | n.a. | n.a. |
| Q4 2018 | 4 | $638m | n.a. | n.a. |
| Q1 2019 | 8 | $1.7bn | n.a. | n.a. |
| Q2 2019 | 8 | $1.9bn | n.a. | n.a. |
| Q3 2019 | 8 | $1.7bn | n.a. | n.a. |
| Q4 2019 | 12 | $2.8bn | n.a. | n.a. |
| Q1 2020 | 9 | $2.3bn | n.a. | n.a. |
| Q2 2020 | 8 | $3.2bn | n.a. | n.a. |
| Q3 2020 | 9 | $4.1bn | n.a. | n.a. |
| Q4 2020 | 12 | $4.5bn | n.a. | n.a. |
| Q1 2021 | 10 | $3.4bn | n.a. | n.a. |
| Q2 2021 | 10 | $3.4bn | n.a. | n.a. |
| Q3 2021 | 10 | $4.5bn | n.a. | n.a. |
| Q4 2021 | 11 | $3.7bn | n.a. | n.a. |
| Q1 2022 | 10 | $3.3bn | n.a. | n.a. |
| Q2 2022 | 9 | $2.5bn | n.a. | n.a. |
| Q3 2022 | 12 | $2.7bn | n.a. | n.a. |
| Q4 2022 | 12 | $3.0bn | n.a. | n.a. |
| Q1 2023 | 9 | $2.6bn | n.a. | n.a. |
| Q2 2023 | 8 | $1.9bn | n.a. | n.a. |
| Q3 2023 | 8 | $2.0bn | n.a. | n.a. |
| Q4 2023 | 11 | $2.8bn | 5 | 7 |
| Q1 2024 | 16 | $3.4bn | 10 | 6 |
| Q2 2024 | 14 | $2.8bn | 8 | 7 |
| Q3 2024 | 15 | $3.1bn | 11 | 5 |
| Q4 2024 | 11 | $2.6bn | 6 | 7 |
| Q1 2025 | 13 | $3.2bn | 7 | 6 |
| Q2 2025 | 11 | $3.2bn | 5 | 6 |
| Q3 2025 | 15 | $3.7bn | 6 | 8 |
| Q4 2025 | 14 | $3.7bn | 16 | 14 |
| Q1 2026 | 10 | $3.1bn | 7 | 25 |
| Q2 2026 | 12 | $4.3bn | 19 | 9 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ASND and LLY →ASND and JNJ →ASND and VRTX →Choose a stock to compare with ASND →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ASND, latest filings →Back to the 13F Explorer →